VYNE THERAPEUTICS INC.

Analyst Reco. VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq Other stock markets 21:30:01 03/05/2024 BST			5-day change	1st Jan Change
2.62 ^USD	+4.80%		+4.80%	+12.45%

04-04	Transcript : VYNE Therapeutics Inc. - Special Call
02-29	VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating	12/05/23	MT
HC Wainwright Adjusts Price Target on VYNE Therapeutics to $28 From $1.50, Maintains Buy Rating	14/03/23	MT
HC Wainwright Cuts VYNE Therapeutics' Price Target to $1.50 From $7, Maintains Buy Rating	10/08/22	MT
HC Wainwright Assumes VYNE Therapeutics at Buy with $7 Price Target	06/12/21	MT
VYNE THERAPEUTICS : Northland Adjusts VYNE Therapeutics' Price Target to $6 From $12, Keeps Outperform Rating	13/08/21	MT
VYNE THERAPEUTICS : HC Wainwright Adjusts VYNE Therapeutics' Price Target to $11 from $14, Keeps Buy Rating	07/05/21	MT
VYNE THERAPEUTICS : Barclays Adjusts Price Target for VYNE Therapeutics to $15 From $12, Maintains Overweight Rating	08/03/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer